WuXi-MedImmune RA Biologic Approved for China Trials

The novel rheumatoid arthritis biologic partnered by WuXi AppTec and MedImmune has been granted CFDA permission to begin clinical trials. The approval came almost two years after the CFDA accepted the molecule's IND filing. The candidate, WBP216 (MEDI5117), is a novel anti-IL-6 antibody that MedImmune modified for extended duration of action. In China, it is a class 1 innovative biologic. The WuXi-MedImmune China JV, which was set up in 2012, is in charge of developing the drug for China. MedImmune is the biologics arm of AstraZeneca. More details.... Stock symbol: (NYSE: AZN) Share this with colleagues: // //